

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. All request for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division ("Assistant Administrator") pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.34(a), this is notice that on June 21, 2017, Organic Standards Solutions International, LLC, 2030 Savage Road, Charleston, South Carolina 29407–2940 applied to be registered as an importer of the following basic classes of controlled substances:

Controlled substance	Drug code	Schedule
Marihuana Extract	7350	I
Marihuana .....	7360	I
Tetrahydrocannabinols.	7370	I

The company plans to import the listed controlled substances to produce analytical reference standards for distribution to its customers. Drug codes 7350 (marihuana extract) and 7360 (marihuana) will be used for the manufacture of cannabidiol only.

Dated: March 21, 2019.

**John J. Martin,**

*Assistant Administrator.*

[FR Doc. 2019–06849 Filed 4–5–19; 8:45 am]

**BILLING CODE 4410–09–P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[Docket No. DEA–392]

#### Bulk Manufacturer of Controlled Substances Registration

**ACTION:** Notice of registration.

**SUMMARY:** The registrant listed below has applied for and been granted a registration by the Drug Enforcement Administration (DEA) as a bulk manufacturer of schedule II controlled substances.

**SUPPLEMENTARY INFORMATION:** The company listed below applied to be registered as a bulk manufacturer of schedule II controlled substances. Information on the previously published notice is listed in the table below. No comments or objections were submitted for this notice.

Company	FR docket	Published
Cambrex High Point, Inc.	83 FR 64159	December 13, 2018.

The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of this registrant to manufacture the applicable basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the DEA has granted a registration as a bulk manufacturer to the above listed company.

Dated: March 21, 2019.

**John J. Martin,**

*Assistant Administrator.*

[FR Doc. 2019–06844 Filed 4–5–19; 8:45 am]

**BILLING CODE 4410–09–P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[Docket No. DEA–392]

#### Importer of Controlled Substances Registration

**ACTION:** Notice of registration.

**SUMMARY:** The registrants listed below have applied for and been granted

registration by the Drug Enforcement Administration (DEA) as importers of schedule I or schedule II controlled substances.

**SUPPLEMENTARY INFORMATION:** The companies listed below applied to be registered as importers of various basic classes of controlled substances. Information on previously published notices is listed in the table below. No comments or objections were submitted and no requests for a hearing were submitted for these notices.

Company	FR docket	Published
Chattem Chemicals ... Research Triangle Institute.	84 FR 2578 84 FR 2571	February 7, 2019. February 7, 2019.

The DEA has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of the listed registrants to import the applicable basic classes of schedule I or II controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated each of the company's maintenance of effective controls against diversion by inspecting and testing each company's physical security systems, verifying each company's compliance with state and local laws, and reviewing each company's background and history.

Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the DEA has granted a registration as an importer for schedule I or schedule II controlled substances to the above listed companies.

Dated: March 21, 2019.

**John J. Martin,**

*Assistant Administrator.*

[FR Doc. 2019–06842 Filed 4–5–19; 8:45 am]

**BILLING CODE 4410–09–P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[Docket No. DEA–392]

#### Importer of Controlled Substances Registration

**ACTION:** Notice of registration.

**SUMMARY:** The registrant listed below has applied for and been granted a registration by the Drug Enforcement Administration (DEA) as an importer of schedule II controlled substances.

**SUPPLEMENTARY INFORMATION:** The company listed below applied to be registered as an importer of various

basic classes of controlled substances. Information on the previously published notice is listed in the table below. No comments or objections were submitted and no requests for hearings were submitted for this notice.

Company	FR docket	Published
Johnson Matthey Inc	83 FR 66750	December 27, 2018.

The DEA has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of the listed registrant to import the applicable basic class of schedule 1 or II controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the DEA has granted a registration as an importer for schedule II controlled substances to the above listed company.

Dated: March 21, 2019.

**John J. Martin,**

*Assistant Administrator.*

[FR Doc. 2019-06843 Filed 4-5-19; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### **Richard Carter, M.D.; Decision and Order**

On October 15, 2018, the Assistant Administrator, Diversion Control Division, Drug Enforcement Administration (DEA), issued an Order to Show Cause to Richard Carter, M.D. (Registrant), of Tifton, Georgia. The Show Cause Order proposed the revocation of Registrant's DEA Certificate of Registration No. AC2515596 on the ground that he "ha[s] no state authority to handle controlled substances." Government Exhibit (GX) 2 (Order to Show Cause) to Government's Request for Final Agency Action (RFAA), at 1 (citing 21 U.S.C. 824(a)(3)). For the same reason, the Order also proposed the denial of "any applications for renewal or modification of such registration and any applications for any other DEA registrations." *Id.*

With respect to the Agency's jurisdiction, the Show Cause Order alleged that Registrant is the holder of Certificate of Registration No. AC2515596, pursuant to which he is authorized to dispense controlled substances as a practitioner in schedules II through V, at the registered address of 2617 Wilson Avenue, Tifton, Georgia. *Id.* The Order also alleged that this registration does not expire until August 31, 2020. *Id.*

Regarding the substantive grounds for the proceeding, the Show Cause Order alleged that on June 12, 2018, the Georgia Composite Medical Board (GCMB) "issued an Order of Summary Suspension summarily suspending [Registrant's] Georgia medical license." *Id.* The Show Cause Order alleged that, as a result, he is "currently without authority to handle controlled substances in the State of Georgia, the [S]tate in which [he is] registered with the DEA." *Id.* Based on his "lack of authority to handle controlled substances in the State of Georgia," the Order asserted that "DEA must revoke" his registration. *Id.* at 1-2 (citing 21 U.S.C. 824(a)(3); 21 CFR 1301.37(b)).

The Show Cause Order notified Registrant of (1) his right to request a hearing on the allegations or to submit a written statement in lieu of a hearing, (2) the procedure for electing either option, and (3) the consequence for failing to elect either option. *Id.* at 2 (citing 21 CFR 1301.43). The Order also notified Registrant of his right to submit a corrective action plan. *Id.* at 2-3 (citing 21 U.S.C. 824(c)(2)(C)).

With respect to service, a Diversion Investigator (DI) in the Savannah Resident Office of DEA's Atlanta Field Division executed a Declaration on February 11, 2019, stating that on November 26, 2018, he "physically mailed the [Show Cause Order] to Registrant's home address at 2617 Wilson Ave. N, Tifton, GA 31794, via United States Postal Service certified mail, return receipt requested." GX 4 (Declaration of DI) to RFAA, at 1-2. The DI also stated in his Declaration that on November 30, 2018, he received the signed return receipt for the Show Cause Order he had mailed on November 26, 2018. *Id.* at 2. The DI attached to his Declaration and authenticated a return receipt from the U.S. Postal Service bearing what appears to be Registrant's signature and indicating that the mailing was delivered to Registrant's address on November 28, 2018. *See id.*; Exhibit (Ex.) B to GX 4, at 2.<sup>1</sup> The DI also

<sup>1</sup> The DI stated that on November 26, 2018, he mailed a second copy of the Show Cause Order to

attached and authenticated a printout from the U.S. Postal Service's website showing that a package with a tracking number matching the one on the return receipt was delivered to Registrant's address on November 28, 2018. *See* GX 4 to RFAA, at 2; Ex. C to GX 4, at 1-2. I therefore find that the Government accomplished service on November 28, 2018.

On March 8, 2019, the Government forwarded its Request for Final Agency Action and evidentiary record to my Office. In its Request, the Government represents that more than 30 days have passed since Registrant had been served with the Show Cause Order and that "Registrant has not requested a hearing and has not otherwise corresponded or communicated with DEA regarding the Order served on him, including the filing of any written statement in lieu of a hearing." RFAA, at 1-2. Based on the Government's representation and the record, I find that more than 30 days have passed since the Show Cause Order was served on Registrant, and he has neither requested a hearing nor submitted a written statement in lieu of a hearing. *See* 21 CFR 1301.43(d). Accordingly, I find that Registrant has waived his right to a hearing or to submit a written statement and issue this Decision and Order based on relevant evidence submitted by the Government and the findings below. *See id.* I make the following findings.

#### **Findings of Fact**

Registrant is the holder of DEA Certificate of Registration No. AC2515596 pursuant to which he is authorized to dispense controlled substances in schedules II through V as a practitioner at the registered address of Richard Carter MD PC, 2617, Tifton, Georgia. GX 1 (Certification of Registration Status) to RFAA, at 1. The "mail to address" is Richard Carter MD PC, 2617 Wilson Avenue, Tifton, Georgia. *Id.* This registration does not expire until August 31, 2020. *Id.*

On June 12, 2018, the GCMB issued an "Order of Summary Suspension" (Suspension Order) suspending Registrant's Georgia medical license based largely on the findings of the North Carolina Medical Board that Registrant "suffered from severe alcohol use disorder" and "was unable to practice medicine with reasonable skill and safety to patients." GX 3 to RFAA,

Registrant's home address "via first-class United States mail, postage prepaid." *Id.* He further stated that "[t]he second copy of the [Show Cause Order] that [he] had mailed via first-class United States mail, postage prepaid, did not come back to the Savannah Resident Office." *Id.*